BRCTF.US BioArctic AB (publ)
- Market cap
- USD 2.69B
- P/E
- 233.3x
- P/B
- 13.18x
- ROE
- 20.1%
- Dividend yield
- 0.70%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BRCTF.US undervalued?
Graham numberThe Graham number of BioArctic AB (publ) cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioArctic AB (publ) fundamental analysis
No fundamental analysis for BioArctic AB (publ) yet.
BioArctic AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and ALS. In addition, it offers lecanemab for intravenous treatment. Further, it is developing lecanemab for subcutaneous treatm…
Full company profileBioArctic AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioArctic AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 106M | 141M | 714M | 282M | 62.3M | 23.1M | 228M | 616M | 257M | 1.99B | 1.37B |
| Gross Profit | 105M | 77.1M | 569M | 209M | 12.1M | -31.9M | 154M | 526M | 230M | 1.94B | 1.29B |
| Operating Income | 74.6M | 19.3M | 489M | 113M | -85.0M | -140M | -17.4M | 253M | -229M | 1.36B | 409M |
| EBITDA | 64.2M | 26.0M | 488M | 123M | -74.8M | -127M | 3.58M | 284M | -177M | 1.38B | 386M |
| Net Income | 57.6M | 15.2M | 382M | 88.5M | -68.5M | -120M | -11.2M | 229M | -177M | 1.02B | 402M |
| EPS | 0.65 | 0.17 | 4.33 | 1.00 | -0.78 | -1.36 | -0.13 | 2.59 | -2.00 | 11 | 4.54 |
| Balance Sheet | |||||||||||
| Total Assets | 708M | 1.14B | 1.39B | 1.18B | 1.05B | 898M | 858M | 1.19B | 1.11B | 2.57B | 2.79B |
| Total Liabilities | 647M | 504M | 375M | 209M | 143M | 109M | 72.1M | 140M | 217M | 607M | 796M |
| Shareholders' Equity | 60.8M | 636M | 1.02B | 974M | 907M | 789M | 786M | 1.05B | 895M | 1.96B | 2.00B |
| Cash & Short-term Investments | 693M | 1.11B | 917M | 1.11B | 1,000M | 848M | 805M | 1.11B | 779M | 2.18B | 1.97B |
| Total Debt | - | - | - | 27.4M | 20.8M | 15.9M | 10.0M | 4.98M | 54.2M | 44.1M | 89.8M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 675M | -135M | -200M | 327M | -92.3M | -140M | -31.6M | 310M | -316M | 1.43B | -58.7M |
| Capital Expenditure | 2.97M | 3.45M | 4.26M | 3.26M | 12.5M | 4.39M | 12.7M | 7.44M | 26.6M | 10.2M | 273M |
| Free Cash Flow | 672M | -139M | -204M | 324M | -105M | -145M | -44.4M | 302M | -343M | 1.42B | -56.3M |
| Ratios | |||||||||||
| ROE | 94.8% | 2.4% | 37.5% | 9.1% | -7.6% | -15.2% | -1.4% | 21.9% | -19.8% | 52.0% | 20.1% |
| ROA | 8.1% | 1.3% | 27.4% | 7.5% | -6.5% | -13.3% | -1.3% | 19.3% | -15.9% | 39.7% | 14.4% |
| Net Profit Margin | 54.5% | 10.8% | 53.4% | 31.4% | -109.9% | -517.5% | -4.9% | 37.2% | -68.8% | 51.1% | 29.4% |
| Debt to Equity | - | - | - | 0.03x | 0.02x | 0.02x | 0.01x | 0.00x | 0.06x | 0.02x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BioArctic AB (publ) dividends
- Dividend yield
- 0.70%
- Forward dividend
- 0.21 USD
- Payout ratio
- -
- Ex-dividend date
- May 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 132M | 1.50 | 149.3% |
| 2018 | USD 132M | 1.50 | 34.6% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns BioArctic AB (publ)
- Insiders 42.34%
- Institutions 31.14%
- Public & others 26.52%
- Shares outstanding 74.3M
- Free float 54.6M
BioArctic AB (publ) company profile
- Company name
- BioArctic AB (publ)
- Ticker
- BRCTF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 150
- Fiscal year end
- December
- Address
- Warfvinges vag 35, Stockholm, Sweden, 112 51
- Phone
- 46 86 95 69 30
- Website
- bioarctic.se
About BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and ALS. In addition, it offers lecanemab for intravenous treatment. Further, it is developing lecanemab for subcutaneous treatment; lecanemab, which is in Phase 3 clinical trials for presymptomatic treatment; exidavnemab, which is in Phase 2 clinical trials; lecanemab back-up, BAN2803, ND3014, and BAN2802, which are in preclinical trials; and ND-BT8825, HD-BT4801, GD-BT6822, ND-BT3814, and PD-BT2238, which are in the research stage. The company has a research and collaboration agreement with Eli Lilly to develop a new drug candidate combining the BrainTransporter technology with a Lilly proprietary molecule, and with Mesenkia Therapeutics to explore a novel antibody-based approach for glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
BioArctic AB (publ) management
10- Dr. Gunilla Osswald Ph.D.President & CEO · born 1961
- Dr. Pär GellerforsCo-Founder & Senior VP of Business Strategy · born 1947
- Prof. Lars LannfeltCo-Founder, Senior VP of Medical science & Director · born 1949
- Mr. Anders Martin-Lof M.B.A., M.Sc.Secretary of the Board & CFO · born 1971
- Mr. Per-Ola FreskgardChief Scientific Officer
- Mr. Oskar BossonVP and Head of IR & Communication · born 1976
- Ms. Emilie Ankarcrona SmithGeneral Counsel and Head of Legal & IP · born 1981
- Mr. Harald BorgekeHead of Public Affairs
- Ms. Frida LekanderHead of Marketing
- Ms. Rebecca KastellVP & Head of HR · born 1978